Partially Purified Gloriosa superba Peptides Inhibit Colon Cancer Cell Viability by Inducing Apoptosis Through p53 Upregulation

被引:23
作者
Budchart, Prapaphan [1 ]
Khamwut, Ariya [1 ]
Sinthuvanich, Chomdao [1 ]
Ratanapo, Sunanta [1 ]
Poovorawan, Yong [2 ]
T-Thienprasert, Nattanan Panjaworayan [1 ]
机构
[1] Kasetsart Univ, Fac Sci, Dept Biochem, 50 Ngamwongwan Rd, Bangkok 10900, Thailand
[2] Chulalongkorn Univ, Fac Med, Ctr Excellence Clin Virol, Dept Pediat, Bangkok, Thailand
关键词
Gloriosa superba; Partially purified peptide; Colon cancer; Apoptosis; p53; COLORECTAL-CANCER; COLCHICINE;
D O I
10.1016/j.amjms.2017.06.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Colon cancer is a major health problem worldwide. Available treatments such as surgery, chemotherapy, radiation and anticancer drugs are limited due to stage of cancer, side effects and altered biodistribution. The use of peptides extracted from natural products has appeared as a potential therapy. Gloriosa superba is known to contain colchicine and other alkaloids with anticancer activity. However, these peptides contained within the extracts have not been studied. This study, therefore, focuses on an investigation of anti colon cancer activity from a partially purified protein hydrolysate of G superba rhizome. Methods: Dried G superba rhizome was extracted using 0.5% sodium dodecyl sulfate and digested with pepsin. The protein hydrolysates with molecular weight lesser than 3 kDa were collected and subjected for cell viability assay. Then, the partial purification of the protein hydrolysate was performed using reverse-phase high-performance liquid chromatography. Fractions containing anticancer peptides were investigated, and their effects on apoptosis and protein expression using apoptosis test and Western blot, respectively. Results: Partially purified peptides of G superba rhizome demonstrated anticolon activity in SW620 cells by inducing apoptosis through upregulation of p53 and downregulation of nuclear factor kappa B (NF-kappa B). Conclusions: Consequently, G superba peptides showed high potential for further purification and development of anticolon therapeutics.
引用
收藏
页码:423 / 429
页数:7
相关论文
共 34 条
[1]   Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials [J].
Aguirre, T. A. S. ;
Teijeiro-Osorio, D. ;
Rosa, M. ;
Coulter, I. S. ;
Alonso, M. J. ;
Brayden, D. J. .
ADVANCED DRUG DELIVERY REVIEWS, 2016, 106 :223-241
[2]   Control of apoptosis by Rel/NF-κB transcription factors [J].
Barkett, M ;
Gilmore, TD .
ONCOGENE, 1999, 18 (49) :6910-6924
[3]   New tricks of an old molecule: lifespan regulation by p53 [J].
Bauer, Johannes H. ;
Helfand, Stephen L. .
AGING CELL, 2006, 5 (05) :437-440
[4]   Inflammation meets cancer, with NF-κB as the matchmaker [J].
Ben-Neriah, Yinon ;
Karin, Michael .
NATURE IMMUNOLOGY, 2011, 12 (08) :715-723
[5]   Role of surgery for colorectal cancer in the elderly [J].
Biondi, Antonio ;
Vacante, Marco ;
Ambrosino, Immacolata ;
Cristaldi, Erika ;
Pietrapertosa, Giuseppe ;
Basile, Francesco .
WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2016, 8 (09) :606-613
[6]   Partially Purified Extracts of Sea Anemone Anemonia viridis Affect the Growth and Viability of Selected Tumour Cell Lines [J].
Bulati, Matteo ;
Longo, Alessandra ;
Masullo, Tiziana ;
Vlah, Sara ;
Bennici, Carmelo ;
Bonura, Angela ;
Salamone, Monica ;
Tagliavia, Marcello ;
Nicosia, Aldo ;
Mazzola, Salvatore ;
Colombo, Paolo ;
Cuttitta, Angela .
BIOMED RESEARCH INTERNATIONAL, 2016, 2016
[7]   Antioxidative properties of partially purified barley hordein, rice bran protein fractions and their hydrolysates [J].
Chanput, Wasaporn ;
Theerakulkait, Chockchai ;
Nakai, Shuryo .
JOURNAL OF CEREAL SCIENCE, 2009, 49 (03) :422-428
[8]  
Chuakul W., 2002, Thai Journal of Phytopharmacy, V9, P22
[9]  
Chung Young-Bae, 2002, Korean Journal of Parasitology, V40, P83, DOI 10.3347/kjp.2002.40.2.83
[10]   The Challenges of Colorectal Cancer Survivorship [J].
Denlinger, Crystal S. ;
Barsevick, Andrea M. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2009, 7 (08) :883-893